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Approximately 300,000 compounds from selected libraries were screened against a subdomain
of a hepatitis C viral (HCV) RNA using a high throughput flow injection mass spectrometry
(FIA-MS) method with automated data storage and analysis. Samples contained 2 M RNA
target and 10 M of each of up to ten ligands. Preliminary studies to optimize operational
parameters used the binding of aminoglycosides to the A44 subdomain of bacterial RNA.
Binding (confirmed by titration) and sensitivity were maximized within the constraints of the
library and throughput. The mobile phase of 5 mM ammonium acetate in 50% isopropanol
maintained the noncovalent complexes and provided good detection by electrospray mass
spectrometry. Additionally, this composition maximized general solubility of the various
classes of compounds including the oligonucleotide and organic library molecules. Cation
adduction was insignificant in this screen although some solute and target dependent acetate
adduction was observed. The ion trap mass spectrometer provided sufficient mass resolution
to identify complexes of RNA with known components of the library. Converted mass spectral
data (netCDF) were subjected to two types of statistical evaluation based on binding. The first
algorithm identified noncovalent complexes that correlated with the molecular weights of the
injected compounds. The second yielded the largest peak in the noncovalent complex region
of the spectrum; this spectrum may or may not correlate with expected well components.
Sixty-three compounds were confirmed to bind by more stringent secondary testing. Titra-
tions, which were carried out with selected binding compounds, yielded a range of dissocia-
tion constants. Biological activity was observed for eleven confirmed binders. (J Am Soc Mass
Spectrom 2004, 15, 884–892) © 2004 American Society for Mass SpectrometryDetection of noncovalent complexes of biologicalmacromolecular targets such as proteins [1] ornucleic acids [2] with drugs by mass spectro-
metry has become a valuable tool in drug discovery [3,
4]. Proteins or nucleic acids that will ionize and yield
good mass spectra can be analyzed by direct methods,
whereas those that are not amenable to mass spectro-
metry due to size or solubility require indirect methods
[3]. Direct detection of noncovalent complexes can be
accomplished by either electrospray ionization (ESI) or
matrix assisted laser desorption ionization (MALDI).
ESI has the advantage of compatibility with chromato-
graphic injection methods and can thus be readily
adapted for high-throughput screening. One require-
ment of the direct detection of noncovalent complexes
by ESI is the ability of the target to ionize in its native
state (conditions in which it binds ligands). Limitations
are usually due to the size or structure of the target or
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for oligonucleotides which are polyanions. When the
ionization is effective, and binding of ligands is retained
throughout the process, ESI yields the molecular weight
of the noncovalent complex and, therefore, the bound
compound. Because ionization is primarily based on the
macromolecule, the ionization characteristics of the
ligand are relatively unimportant, thus providing a
general screening method for a diverse library.
RNA is a validated drug target as substantiated by
the use of erythromycin and aminoglycosides as anti-
bacterial agents [5–7]. Functional domains of several
RNA substructures have been shown to retain their
binding capabilities during ESI/MS [2, 8]. Noncovalent
complexes of oligonucleotides are formed in the pres-
ence of organic solvent and millimolar concentrations of
salt, conditions which are compatible with flow injec-
tion mass spectrometry in the negative ion mode.
Screening compound libraries against RNA targets has
also been successfully undertaken [8, 9], as has deter-
mining structure-activity relationships (SAR) by mass
spectrometry [8]. Most studies of noncovalent com-r Inc. Received November 3, 2003
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correlate with those of the solution phase [2, 10].
One well-studied subdomain of 16S bacterial rRNA
is the A44 domain. The binding of aminoglycoside antibi-
otics to A44 has been examined in detail using mass
spectrometry in terms of both dissociation constants
and binding sites [2, 11]. Figure 1 illustrates the struc-
tures of A44 and paromomycin, an aminoglycoside
which has a dissociation constant of about 0.1 M [12].
This paper describes the high-throughput screening
(HTS) of approximately 300,000 compounds from se-
lected libraries against a subdomain of Hepatitis C viral
(HCV) RNA. Flow injection analysis (FIA) with detec-
tion by negative ion electrospray ionization mass spec-
trometry (ESI/MS) on an ion trap instrument provided
a robust method to screen up to 10,000 compounds per
day. The automated system included pooling of the
potential ligands, mixing with target, high/low flow
rates and data analysis, ultimately yielding ranked lists
based on noncovalent binding to the target, peak cor-
relation between the target and the complex, and signal
intensities.
Experimental
Pooling
Library compounds from multiple libraries, 10 mM in
dimethylsulfoxide (DMSO), were diluted and pooled to
a final concentration of 11.4 M each in 5 mM ammo-
nium acetate in 50% isopropanol (1% DMSO). A
Tecan (Research Triangle Park, NC) Genesis Worksta-
tion 200 with CCS Packard (Torrance, CA) PlateStak
plate stackers pooled up to ten ligands per well auto-
matically using predefined pooling rules, bar coded
plates and customized software described elsewhere [13].
Figure 1. Structures of A44 subdomain of 16S RNA, the control
bacterial target, and paromomycin, an aminoglycoside. Structures
were drawn with RNAdraw [15].Flow Injection-Mass Spectrometry
The pooled library compounds were mixed, one row at
a time, with 5 l RNA (20 M in 50 mM ammonium
acetate in 50% isopropanol) and then injected into eight
2 l injection loops simultaneously using a Tecan robot.
The final concentrations were 2 M RNA and 10 M
ligand. Parallel sets of injection loops allowed adequate
washing to occur. A programmable logic controller
(PLC) controlled the timing of each injection (one every
30 s), and sent a contact closure signal to the mass
spectrometer to begin each acquisition. After the acqui-
sition of data for each row of samples, the raw files were
converted to netCDF format and stored in a local
database to allow easy retrieval and interpretation. The
details of this process are described elsewhere [13]. The
A44 subdomain of 16S rRNA (1 M) was used as a
control, bracketing each set of eight injections.
Shimadzu (Columbia, MD) LC10-AD HPLC pumps
were controlled by a PLC for high and low flow rates.
The timing was checked and adjusted daily, if neces-
sary, to account for any slight changes in volume of the
tubing. A ThermoFinnigan (San Jose, CA) LCQ Classic
with a steel needle was used. The mobile phase was 5
mM ammonium acetate in 50% isopropanol. All re-
agents were HPLC grade.
RNA
The synthesized subdomains of RNA were obtained
from Dharmacon Research, Inc. (Lafayette, CO) and
Qiagen-Xeragon (Valencia, CA). The RNA was used as
received if there was not excessive metal cation adduc-
tion in the mass spectrum. If cation adduction was high,
the RNA was further purified by reversed phase solid
phase extraction or HPLC using triethylamine as an
ion-pairing agent to replace the metal.
Results and Discussion
RNA Targets
Feasibility studies and methods were developed with
the A44 substructure of 16S RNA which has a molec-
ular weight of 8635 Da. A44 is known to bind
aminoglycosides such as paromomycin [6, 7]. Figure
1 illustrates the structures of this target and ligand
pair. The target oligonucleotide in the high through-
put screen described in this paper was SL-3e, a
14-mer substructure of Hepatitis C viral (HCV) RNA.
It has a molecular weight of 4501 Da, and is shown in
Figure 2. It was absolutely necessary that the oligo-
nucleotides be pure and free of most metal cations to
ensure that only one major ion would be observed by
mass spectrometry. Metal cations were replaced with
volatile cations by reversed phase solid phase extrac-
tion or HPLC.
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Compounds from several libraries, totaling almost
300,000, were pooled with up to ten per well using a
novel clique-based algorithm to identify compatible sets
of molecules based on reactivity rules and molecular
weight overlap. Approximately 100 plates containing 88
wells of individual compounds were pooled each day
into 13–15 destination plates. The library compounds
were obtained in a DMSO solution and required dilu-
tion to a solution compatible with binding to the
oligonucleotide target. A composition of 5 mM ammo-
nium acetate in 50% isopropanol containing less than
1% DMSO yielded a good compromise for facilitating
both complex formation and solubility of the RNA and
library compounds. An aliquot of each well in the
destination plate was mixed with the oligonucleotide
target immediately before injection to produce final
Figure 2. Structure of SL-3e subdomain of RNA [16]. Structure
was drawn with RNAdraw [15].
Figure 3. Design of the high throughput flsample concentrations of 2 M target and 10 M of each
ligand in 10 mM ammonium acetate in 50% isopropanol.
High Throughput Instrumentation
The general process and components of this high
throughput system are diagrammed in Figure 3. The
bar-coded plates allowed continuity of the process from
pooling to data analysis. The design of the specialized
injector and the software which controlled the processes
are described in detail elsewhere [13].
Because the goal of this screen was a high through-
put method, instrumental parameters were optimized
to achieve a total analysis time of 30 s per injection. The
prerequisite of the mobile phase was that it both pre-
serve the integrity of the noncovalent complex and
enhance detection by negative ion ESI. The suitability of
the system using 5 mM ammonium acetate in 50%
isopropanol was verified by the excellent spectral qual-
ity and preservation of the noncovalent A44-paromo-
mycin complex seen in the spectra in Figure 4.
The injector was designed in-house to accommodate
this high throughput method. It consisted of two par-
allel eight injector units which mixed the compounds of
one row with target and then injected them simulta-
neously. The low dead-volume system resulted in only
minimal additional band spreading to the flow injection
peaks. The parallel design provided enough time to
achieve thorough washing of the loops between sam-
ples. Carryover was occasionally observed due to the
diverse sample set but it was minimized by the washing
procedures with the mobile phase.
A high/low flow injection procedure was imple-
mented to quickly move the sample to the ESI source at
200 l/min, while providing washing of the tubing.
During sample injection into the source, the flow was
jection analysis-mass spectrometer system.ow in
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LCQ ion trap mass spectrometer was tuned at that low
flow rate to maximize signal. Timing was checked daily
and adjusted accordingly to compensate for small vari-
ations in system volume due to tubing expansion or
blockage. The first and last injections of the 10 sample
set were A44 controls to assess performance. The mid-
dle eight peaks were the injected samples.
Figure 4 illustrates a chromatogram and spectra of
A44, the control oligonucleotide (m/z 1727), and its
noncovalent complex with paromomycin (m/z 1850)
during the lower levels of a titration. Each of the eight
wells contained 2 M A44. Wells 2, 3, 5, and 7 also
contained 0.5, 1, 2, and 4 M paromomycin, respec-
tively. The upper mass chromatogram, corresponding
to the noncovalent complex, showed an increase during
titration, whereas the lower mass chromatogram of the
target ions concomitantly decreased. By a concentration
of 4 M paromomycin, most of the target had been
bound to the drug. Binding (B) was calculated by the
areas of complex/(target  complex). Total binding
would thus have a B value of 1. These data were used to
generate the binding curve shown in Figure 5. The KD
obtained from the titration was 0.28 M with a 95%
confidence interval and is similar to dissociation
constants obtained in other studies [9, 11]. Due to the
limits of detection of this high throughput system, it
was not possible to use levels of RNA below 2 M
Figure 4. Titration of A44 (R) with paromom
shows mass chromatogram of the A44/parom
chromatogram of the A44 target at m/z 1727. Fir
A44 alone. At 0.5 M paromomycin, shown at
observed in the mass spectrum. At bottom left
included 1 M paromomycin. The signal of the
the amount of paromomycin increased in injectwhich would have yielded more precise values of KD
[11]. At the 2 M level, it was possible to detect
noncovalent complex formation, identify the ligand if
it was one of the well components, and obtain a
general range of binding (i.e., KD  10 M). The
method was thus sufficient to classify the ligands as
weak, strong or medium binders.
(L) using FIA with high/low flow. Upper left
cin complex (RL) at m/z 1850 and the mass
d last peaks are bracketing control injections of
center, the complex peak at m/z 1850 was not
complex can be seen in injection no. 2 which
lex increased and the target signal decreased as
o. 3, no. 5, and no. 7 as shown on the right.
Figure 5. Titration curve generated by the noncovalent binding
of A44 with paromomycin. KD  0.28 M with a 95% confidence
interval.ycin
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During method development, experimental design us-
ing JMP software (SAS Institute, Cary, NC) was used to
expedite the optimization of the MS detection of non-
covalent complexes of RNA with aminoglycosides. The
experiments screened seven different factors in order to
determine the main effects in the optimization. Those
factors included capillary temperature, sheath gas flow
rate, auxiliary gas flow rate, pH of the mobile phase, ESI
voltage, mobile phase flow rate and the percentage of
organic solvent in the mobile phase. The objective was
to preserve the noncovalent complex and obtain the
maximum absolute signal and minimal cation adduc-
tion. The main effects were caused by the sheath gas
flow rate, the percentage of organic solvent, and the
flow rate of the mobile phase. After optimization of
these parameters, the instrument was tuned to maxi-
mize the oligonucleotide target signal using a combina-
tion of manual and automated tuning. The automatic
gain control was turned off and a 200 ms injection time
was employed. High-mass calibration was performed
weekly using a sodium iodide solution and the vacuum
level was monitored closely to obtain early warning of
obstruction of the heated capillary. A sheath gas com-
posed of oxygen/nitrogen [11] was used in preliminary
studies but subsequent comparison with a sheath gas of
100% nitrogen demonstrated no advantage in detection
of noncovalent complexes in this HTS FIA-MS method;
Figure 6. Noncovalent Binding of SL-3e with
chromatogram represents eight injections (plus t
HCV target. Each injection contained the target a
for injection no. 6 illustrates the formation of aconsequently, 100% nitrogen was selected for conve-
nience and cost.
The high-throughput FIA system had to operate unat-
tended for approximately 18 h per day, four days per
week. This requirement for a robust system prompted
the replacement of the standard fused silica capillary
tubing with a stainless steel needle kit to introduce
samples into the ion trap. The large i.d. of the
32-gauge needle virtually eliminated plugging in the
ESI source despite the inevitable introduction of
samples that had limited or no solubility in the mobile
phase. This substitution also eliminated the need for the
occasional operator intervention required to correct
slippage of the fused silica tubing in the spray needle.
The 45 day screen had 97% uptime with routine main-
tenance being performed weekly.
Spectral Data
The spectra were generally of good quality with signal-
to-noise ratio of at least 100 for 2 M oligonucleotide.
The SL-3e 14-mer target oligonucleotide of molecular
weight 4502 produced both 3 and 4 charge states
using this negative ion mass spectrometry procedure.
Noncovalent complexes were usually observed in both
charge states (Figure 6) but sometimes only the4 charge
state was formed. The mass chromatograms in Figure 6
show the SL-3e RNA target alone in the top portion, the
gands (injections no. 2 and no. 6). The mass
jections of controls) in the primary screen of the
ine potential ligands. The summed mass spectra
valent complex at m/z 1242.2 li
wo in
nd n
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plexes in the bottom. It can be seen that a decrease in
target was accompanied by an increase in complex in
wells 2 and 6, which each contained a compound
confirmed to bind to the target. Each of these wells
additionally contained eight other compounds which
did not form noncovalent complexes. The spectrum of
injection 6 in the bottom panel very clearly indicates the
complex peaks as well as the target, despite the pres-
ence of the eight other substances. The signal-to-noise
ratio was greater than 100 in this example. No back-
ground subtraction or other data smoothing were done
on the data.
Generally, little cation adduction was observed.
Some samples, which were from diverse sources and
contained varying amounts and composition of salts,
produced significant adduction. This can be seen in the
spectrum shown in Figure 7 from the third injection of
the set (1.5–2.0 min). The salt sometimes increased the
total ionization current and produced a significant 2
charge state peak, possibly indicating a concomitant pH
change. This phenomenon usually resulted in a large
TIC peak (bottom row) and decreased target (top row)
due to the formation of an envelope of peaks instead of
a discrete peak. When these samples were reanalyzed
with a higher ammonium acetate concentration, the
extensive adduction was either eliminated or greatly
decreased. This may indicate a mixing or solubility
problem during the primary HTS procedure or, more
probably, replacement of the original cations with am-
monium.
Figure 7. Mass chromatogram and spectrum
chromatogram (TIC) in the lower trace is very h
upper trace is very low for this injection (1.5–2.The other adduction which was commonly observed
was that of acetate, as shown in Figure 8 for both the3
and4 charge states. Certain compounds and/or target
RNA structures seemed to enhance this adduction. The
FIA-MS procedure described in this report was used to
analyze more than ten substructures of RNA of various
molecular weights. The extent of acetic acid adduction
was structure dependent when purified target was
analyzed with the ammonium acetate/isopropanol mo-
bile phase in solutions without any ligands. When
collision induced dissociation was applied to the oligo-
nucleotide-acetate complex, bond fragmentation oc-
curred before loss of the acetate. Stable noncovalent
anionic adducts of carbohydrates have been observed in
other studies [14].
Data Acquisition and Analysis
The data files, which contained eight injections brack-
eted by controls, were acquired using Xcalibur soft-
ware (ThermoFinnigan, San Jose, CA). Data were
then transferred to a server and analyzed by a master
program that identified peaks in the noncovalent
complex region of the spectrum and their correlation
with the known components of the well. Various
attributes such as target and complex area under the
curve (AUC), binding (B  complex/[target  com-
plex]), and correlation of the elution of the noncova-
lent complex peak to that of the target were assessed
and presented in a JMP database. The results could
then be compared and complexes identified by man-
highly adducted target. The total ion current
nd the mass chromatogram for the target in the
).of a
igh a
0 min
A su
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was the Ligand Lookup table in which the binding and
the AUC for every library component with target was
assessed. The second was the Ligand Scan table in
which only the highest peak in the noncovalent
complex region of each injection was noted. In some
cases, this was correlated with a noncovalent complex
of a known component or an adduct thereof. In
others, the peaks resulted from aggregated ligands or
unknowns. Figure 9 shows the graphed data of each
statistical analysis method for one batch of 14 desti-
Figure 8. Acetate adduction of the SL-3e RN
Figure 9. Statistical Presentation of Binding.
binding (B). (a) Ligand Lookup: Correlated with
injection (may or may not correlate with well conation plates pooled from about 10,000 compounds.
Compounds which produced noncovalent complexes
with significant binding and correlation were se-
lected for confirmation by secondary testing.
The success of injections was assessed by the sum of
the target and complex AUC to accommodate cases of
either negligible or total binding. False positives were
observed when substances associated as dimers or
other aggregates. The diversity of the library included
compounds of differing solubility in aqueous solvents;
therefore, aggregation of some species in this or any
bdomain. m/z 1125.1 is the 4 charge state.
sum of target plus complex is plotted against
d in the well. (b) Ligand Scan: Highest peak in
ts).The
ligan
nten
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exhibited a sodium adduct as well as a single charge
state which could be verified by acquiring higher reso-
lution spectra (using the ZoomScan feature on the LCQ
Classic) or by analyzing the sample on a Fourier trans-
form ion cyclotron resonance spectrometer (FT-ICR).
Secondary confirmation of binding delineated samples
with a two step process which included high/low flow
injection analysis of the possible ligand without and
with the oligonucleotide, thus elucidating “ligands
only” phenomena.
Secondary Confirmation of Binding
Compounds which appeared to form noncovalent com-
plexes with the RNA substructure were reanalyzed
without and with target on another FIA-MS system.
This method implemented a single injection port and
automatic mixing of the sample with target. High/low
flow with the same mobile phase as in the primary
screening resulted in similar spectra when binding did
confirm. A higher salt concentration of 50 mM ammo-
nium acetate in 50% isopropanol was used for the
complex formation so that nonspecific interactions due
to ionic forces would be minimized [8]. This was higher
than the 10 mM salt in the sample in the primary HTS
method.
A representative sampling of confirmed binders to
include compounds from different classes of quater-
nary salts, aminoglycosides, peptides, and neutral
molecules, were titrated against the target. They
exhibited dissociation constants ranging from M to
mM binding. Biological activity was assayed on all
compounds confirmed to form noncovalent com-
plexes. Sixty-three compounds with B values greater
than 0.1 in the primary screening were confirmed
to bind in the secondary assay. Eleven of these, as
listed in Table 1, exhibited biological activity. When
the eleven active compounds were titrated to the
target RNA substructure, three were strong binders
(KD  10 M), three were intermediate (KD  10 –50
M) and four were weak ( K  100 M). The
Table 1. Ligands with biological activity
No. Compound class
MS Binding
Biological
assays IC50
IRES (M)
B (10 M
ligand)
KD
(M)
1 Peptide 0.30 10–50 3.3
2 Neutral 0.02 100 3.76
3 Aminoglycoside 0.50 10 4.4
4 Quaternary amine weak 5.87
5 Quaternary amine 0.04 100 7.37
6 Peptide 0.35 10 7.8
7 Aminoglycoside Plugged system 7.57
8 Quaternary amine 0.05 100 10.87
9 Peptide 0.05 10–50 11.48
10 Aminoglycoside 0.60 10 11.95
11 Peptide 0.30 10–50 12.6Dother compound was not totally soluble in the
mobile phase and was not titrated to avoid plug-
ging the system. Its B value of 0.44 in the primary
HTS would suggest that it was also a tight binder.
Only the confirmed binders with biological activity
had KD values indicating strong or intermediate
binding. All biologically active compounds were ti-
trated but only a representative number of the inac-
tive ones were.
The spectral properties regarding charge state and
multiple binding were also noted. Both charge states
were usually observed. With the peptide ligands, how-
ever, only the 4 charge state was observed; these also
tended to yield high acetic acid adducts. Due to these
anomalies, peptide ligands were not generally detected
by the Ligand Lookup data analysis program but were
earmarked by the Ligand Scan. Most active ligands did
not exhibit multiple binding to the target except at high
levels during titration.
Conclusions
High throughput screening of library compounds
against oligonucleotide targets was achieved with a
flow injection analysis-negative ion mass spectrometry
method. Ligands that formed noncovalent complexes
were generally from the classes of compounds previ-
ously found to bind to RNA: Peptides, aminoglyco-
sides, and cations [8]. Many other compounds in these
classes were included in the library and did not form
noticeable noncovalent complexes, showing selectivity
for the method. The subset of compounds selected by
the screen provided eleven compounds which also had
biological activity and strong to intermediate binding
characteristics. The screening method was robust, with
97% uptime.
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